Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
FB Plus
- Development stage
- Phase 2
- Lead developer
- KCFB
- Modality
- Cell Therapies
- Administration
- Topical
01
Overview
FB Plus (also written as FBPlus) is an allogeneic cell therapy product consisting of an epidermal and dermal substitute containing allogeneic fibroblasts. Developed by HMG Biologics (the Italian operating company of KCFB) in collaboration with Swiss Stem Cells Biotech, FB Plus is designed for the treatment of chronic wounds, including chronic leg and foot ulcers (chronic lower limb ulcers) and bedsores. The therapy utilizes human cells as biocarriers of alarmins, specifically HMGB1 group proteins, which promote tissue regeneration and repair by restoring the normal microenvironment of the wound bed. FB Plus has been applied to over 1,500 patients under Italian Medicines Agency (AIFA) authorization, demonstrating significant clinical efficacy and safety, and is undergoing Phase 1/2 clinical development.
- Other names
- FBPlus
Beyond the preview
Go deeper on FB Plus.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on FB Plus.